Claims for Patent: 6,858,618

Summary for Patent: 6,858,618

Title:	Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Abstract:	The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
Inventor(s):	Raza; Ali (Cheshire, GB), Hutchinson; Howard Gerard (Delaware, DE)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	10/432,402
Patent Claims:	1. A method for treating heterozygous familial hypercholesterolemia in a patient suffering heterozygous familial hypercholesterolemia, comprising administering to the patient (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof. 2. A method as claimed in claim 1 wherein the patient is suffering from severe heterozygous familial hypercholesterolemia. 3. A method as claimed in claim 1 wherein the patient also suffers one or more of the following conditions coronary heart disease, peripheral vascular disease and diabetes. 4. A method as claimed in claim 1 or claim 3 wherein the target LDL-C level for the patient suffering heterozygous familial hypercholesterolemia which is to be achieved by administering to the patient (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof is less than or equal to .ltoreq.100 mg/dL. 5. A method as claimed in claim 4 wherein the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid is administered. 6. A method as claimed in claim 5 wherein 40 to 80 mg of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5 S)-3,5-dihydroxyhept-6-enoic acid is administered once a day to the patient in the form of the calcium salt. 7. A method as claimed in claim 5 wherein 80 mg of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid is administered once a day to the patient in the form of the calcium salt. 8. A method for reducing LDL-C, raising HDL-C, reducing Apo B and raising Apo A-I in a patient suffering from heterozygous familial hypercholesterolemia comprising administering to the subject (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof. 9. A method as claimed in claim 1 wherein the patient has a fasting LDL-C level between 5.69 and <12.93 mmol/L. 10. A method as claimed in claim 9 wherein the patient has a fasting triglyceride level less than or equal to 4.52 mmol/L.